tiprankstipranks
Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial
Company Announcements

Shuttle Pharmaceuticals Advances Phase 2 Glioblastoma Trial

Don't Miss Our Christmas Offers:

Shuttle Pharmaceuticals Holdings, Inc. ( (SHPH) ) has issued an announcement.

Shuttle Pharmaceuticals has announced the successful dosing of the first three patients in its Phase 2 clinical trial of Ropidoxuridine, a promising radiation sensitizer for glioblastoma treatment. With Orphan Drug Designation from the FDA, this trial aims to improve survival rates for patients suffering from this aggressive brain cancer. The study, expected to conclude in 18 to 24 months, could significantly expand the market for radiation sensitizers, which is anticipated to grow by over 22% in the next five years.

For a thorough assessment of SHPH stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyShuttle Pharmaceuticals enters into sponsored research agreement with UCSF
TipRanks Auto-Generated NewsdeskShuttle Pharmaceuticals Starts Phase 2 Trial for Glioblastoma
TheFlyShuttle first patient enrollment, dosing in Phase 2 Ropidoxuridine line
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App